title: Impact of Brachyury on epithelial-mesenchymal transitions and chemosensitivity in non-small cell lung cancer.
abstract: The objective of the current study was to investigate the impact of Brachyury on epithelial-mesenchymal transitions and chemosensitivity in non-small cell lung cancer (NSCLC). In 115 archived NSCLC tissue samples, the expression of Brachyury was observed to be significantly higher than that in adjacent normal lung tissues. In addition, the current study demonstrated that the expression of Brachyury is closely associated with TNM staging, lymph node metastasis and the prognosis of NSCLC, although not with patient age, gender or tumor differentiation. Brachyury expression is also accompanied by the downregulation of E-cadherin and the upregulation of N-cadherin. Brachyury may promote lung cancer through induction of epithelial-mesenchymal transition, which leads to metastasis and consequent poor prognosis in patients with lung cancer. Furthermore, the present study observed that interfering with Brachyury increases the sensitivity of cells to chemotherapeutic treatment with cisplatin. These results, in combination with those of additional studies, suggest that Brachyury may be used as a novel target for the prevention and treatment of lung cancer.
authors: Department of Thoracic Surgery, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning 110042, P.R. China.
authors: Ke
authors: K
authors: Xu
authors: Department of Medical Oncology, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning 110042, P.R. China.
authors: Bin
authors: B
authors: Liu
authors: Department of Thoracic Surgery, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning 110042, P.R. China.
authors: Yongyu
authors: Y
authors: Liu
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015703:Antigens, CD / Q000235:genetics / Q000378:metabolism; D000970:Antineoplastic Agents / Q000494:pharmacology; D015820:Cadherins / Q000235:genetics / Q000378:metabolism; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics* / Q000378:metabolism / Q000401:mortality / Q000473:pathology; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D002945:Cisplatin / Q000494:pharmacology; D019008:Drug Resistance, Neoplasm / Q000187:drug effects / Q000235:genetics; D058750:Epithelial-Mesenchymal Transition / Q000235:genetics*; D005260:Female; D005326:Fetal Proteins / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000378:metabolism; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000401:mortality / Q000473:pathology; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D034741:RNA, Small Interfering / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction; D016019:Survival Analysis; D020825:T-Box Domain Proteins / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000378:metabolism; D000098908:Brachyury Protein
chemical_list: D015703:Antigens, CD; D000970:Antineoplastic Agents; D015820:Cadherins; D002945:Cisplatin; D005326:Fetal Proteins; D034741:RNA, Small Interfering; D020825:T-Box Domain Proteins; D000098908:Brachyury Protein; C050361:CDH2 protein, human